|
1
|
Mangana J, Zipser MC, Conrad C, Oberholzer
PA, Cozzio A, Knuth A, French LE and Dummer R: Skin problems
associated with pegylated liposomal doxorubicin - more than
palmoplantar erythrodysesthesia syndrome. Eur J Dermatol.
18:566–570. 2008.PubMed/NCBI
|
|
2
|
Green AE and Rose PG: Pegylated liposomal
doxorubicin in ovarian cancer. Int J Nanomedicine. 1:229–239.
2006.PubMed/NCBI
|
|
3
|
Cady FM, Kneuper-Hall R and Metcalf JS:
Histologic patterns of polyethylene glycol-liposomal
doxorubicin-related cutaneous eruptions. Am J Dermatopathol.
28:168–172. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Farr KP and Safwat A: Palmar-plantar
erythrodysesthesia associated with chemotherapy and its treatment.
Case Rep Oncol. 4:229–235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
von Moos R, Thuerlimann BJ, Aapro M,
Rayson D, Harrold K, Sehouli J, Scotte F, Lorusso D, Dummer R,
Lacouture ME, et al: Pegylated liposomal doxorubicin-associated
hand-foot syndrome: Recommendations of an international panel of
experts. Eur J Cancer. 44:781–790. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sobin LH, Gospodarowicz MK and Wittekind
C: Ovary cancerTNM Classification of Malignant Tumours. 7th.
Wiley-Blackwell; Hoboken, NJ: pp. 222–226. 2009
|
|
7
|
National Cancer Institute, . Common
Terminology Criteria for Adverse Events (CTCAE) version 4.03.
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfAccessed
June 14, 2010.
|
|
8
|
Lorusso D, Di Stefano A, Carone V, Fagotti
A, Pisconti S and Scambia G: Pegylated liposomal
doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’
syndrome). Ann Oncol. 18:1159–1164. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Skelton H, Linstrum J and Smith K:
Host-vs.-altered-host eruptions in patients on liposomal
doxorubicin. J Cutan Pathol. 29:148–153. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
English JC III, Toney R and Patterson JW:
Intertriginous epidermal dysmaturation from pegylated liposomal
doxorubicin. J Cutan Pathol. 30:591–595. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vidal C, Afonzo Y, Abal C and Rondón M: A
grade IV maculopapular skin lesion associated with pegylated
liposomal doxorubicin. MOJ. 2:57–59. 2012.
|
|
12
|
Martschick A, Sehouli J, Patzelt A,
Richter H, Jacobi U, Oskay-Ozcelik G, Sterry W and Lademann J: The
pathogenetic mechanism of anthracycline-induced palmar-plantar
erythrodysesthesia. Anticancer Res. 29:2307–2313. 2009.PubMed/NCBI
|
|
13
|
Kim RJ, Peterson G, Kulp B, Zanotti KM and
Markman M: Skin toxicity associated with pegylated liposomal
doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.
Gynecol Oncol. 97:374–378. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jacobi U, Waibler E, Schulze P, Sehouli J,
Oskay-Ozcelik G, Schmook T, Sterry W and Lademann J: Release of
doxorubicin in sweat: First step to induce the palmar-plantar
erythrodysesthesia syndrome? Ann Oncol. 16:1210–1211. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yokomichi N, Nagasawa T, Coler-Reilly A,
Suzuki H, Kubota Y, Yoshioka R, Tozawa A, Suzuki N and Yamaguchi Y:
Pathogenesis of hand-foot syndrome induced by PEG-modified
liposomal doxorubicin. Hum Cell. 26:8–18. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Macedo LT, Lima JP, dos Santos LV and
Sasse AD: Prevention strategies for chemotherapy-induced hand-foot
syndrome: A systematic review and meta-analysis of prospective
randomised trials. Support Care Cancer. 22:1585–1593.
2014.PubMed/NCBI
|
|
17
|
Templeton AJ, Ribi K, Surber C, Sun H, Hsu
Schmitz SF, Beyeler M, Dietrich D, Borner M, Winkler A, Müller A,
et al: Prevention of palmar-plantar erythrodysesthesia with an
antiperspirant in breast cancer patients treated with pegylated
liposomal doxorubicin (SAKK 92/08). Breast. 23:244–249. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ,
Kim MS, Ryu MH, Chang HM, Lee JL and Kim TW: Pyridoxine is not
effective to prevent hand-foot syndrome associated with
capecitabine therapy: Results of a randomized, double-blind,
placebo-controlled study. J Clin Oncol. 28:3824–3829. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
von Gruenigen V, Frasure H, Fusco N,
DeBernardo R, Eldermire E, Eaton S and Waggoner S: A double-blind,
randomized trial of pyridoxine versus placebo for the prevention of
pegylated liposomal doxorubicin-related hand-foot syndrome in
gynecologic oncology patients. Cancer. 116:4735–4743. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lopez AM, Wallace L, Dorr RT, Koff M,
Hersh EM and Alberts DS: Topical DMSO treatment for pegylated
liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
Cancer Chemother Pharmacol. 44:303–306. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Drake RD, Lin WM, King M, Farrar D, Miller
DS and Coleman RL: Oral dexamethasone attenuates Doxil-induced
palmar-plantar erythrodysesthesias in patients with recurrent
gynecologic malignancies. Gynecol Oncol. 94:320–324. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Najem A, Deregnaucourt D, Ramdane S,
Dridba M, Djouba F and Vercambre-Darras S: Intertrigo-like
dermatitis with pegylated liposomal doxorubicin: Diagnosis and
management. J Clin Oncol. 32:e104–e106. 2014. View Article : Google Scholar : PubMed/NCBI
|
